Status:
COMPLETED
CIQTP Prolongation : Role and Mechanism in Sudden Cardiac Death
Lead Sponsor:
Nantes University Hospital
Conditions:
Sudden Cardiac Death
Eligibility:
All Genders
Brief Summary
Despite major progress in molecular and phenotypic characterization of primary electrical disorders, many (aborted) sudden cardiac deaths (SCD) occur in young victims without identifiable abnormalitie...
Detailed Description
Sudden cardiac death (SCD) is a major cause of death in developed countries. An estimated 40,000 to 50,000 individuals die suddenly each year in France. Most of these deaths involve elderly people and...
Eligibility Criteria
Inclusion
- Relatives seen for a familial screening after an unexplained sudden cardiac death in a young member of their family (\<45 years old).
- Patients affected with CIQTP characterized by normal QT duration at rest but major QT lengthening during mental stress test
- Signed consent
Exclusion
- Patients who underwent a sudden cardiac death with an identified cause of the decease after an autopsy
- Patients under trusteeship or under guardianship
- Patients who didn't give their consent or who is not able to
Key Trial Info
Start Date :
March 14 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 16 2021
Estimated Enrollment :
394 Patients enrolled
Trial Details
Trial ID
NCT03387072
Start Date
March 14 2018
End Date
March 16 2021
Last Update
March 17 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Brest University Hospital
Brest, France, 29609
2
Nantes University Hospital
Nantes, France, 44093
3
Rennes University Hospital
Rennes, France, 35000
4
Tours University Hospital
Tours, France, 37000